Medicenna Therapeutics Corp

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TORONTO and HOUSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with Oppenheimer & Co. Inc. (“Oppenheimer & Co.”) acting as sales agent (the “Sales Agreement”), pursuant to which the Company may, from time to time, sell through “at-the-market” offerings on the Nasdaq Capital Market (the “Nasdaq”) such number of common shares that would have an aggregate offering price of up to US$10 million (the “ATM Offering”) under the ATM Prospectus Supplement (as defined below). Medicenna will determine, at its sole discretion, the time, minimum price and maximum number of common shares to be sold under the ATM Offering.

Medicenna Establishes At-the-Market Sales Facility

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q3 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Fahar Merchant - President and Chief Executive Officer Liz Williams - Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Matt Biegler - Oppenheimer David Martin - Bloom Burton RK - H.C. Wainwright Catherine Novack - Jones Research David Bautz - Zacks Small-Cap Research Operator Hello and welcome to the Medicenna Therapeutics Fiscal Third Quarter Earnings Call.

Medicenna Therapeutics Corp. (MDNA) Q3 2023 Earnings Call Transcript

TORONTO and HOUSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the quarter ended December 31, 2022, and that the Phase 1/2 ABILITY study of MDNA11 has advanced to a sixth dose escalation cohort. All dollar amounts are in Canadian currency unless otherwise noted.

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.

Medicenna to Present at the 2023 Guggenheim Oncology Conference

TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights.

Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023

- Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT ™

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent

- MDNA11's selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q2 2023 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants David Martin - Bloom Burton Catherine Novack - Jones Search Operator Hello and welcome to the Medicenna Therapeutics' Fiscal Second Quarter Earnings Call. All participants are in a listen-only mode.

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2023 Earnings Call Transcript

- Results from low and mid-dose escalation cohorts in Phase 1/2 ABILITY study show tumor control in 5 of 14 evaluable patients, including a confirmed partial response in pancreatic cancer

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq, and the Company's operations are not affected by the receipt of the Notice.

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM ET to report its second quarter fiscal 2023 financial results and operational highlights.

Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

TORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company's “beta-only” long-acting IL-2 super-agonist. These data include a confirmed partial response (PR) in a fourth-line metastatic pancreatic ductal adenocarcinoma (PDAC) patient that had previously failed chemo and checkpoint inhibitor therapies. The confirmatory scan for this patient continues to show further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy. Overall, five of fourteen evaluable patients in the ABILITY study's low and mid-stage dose escalation cohorts have achieved tumor control (PR or stable disease (SD)) with MDNA11 monotherapy.

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck's KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumors ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck's KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumors

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and scientific conferences this month:

Medicenna to Present at Investor and Scientific Conferences in September

Longboard Pharmaceuticals

Penny stocks are shares usually below $5, representing small companies, most of which trade by over-the-counter (OTC) transactions, while there

2 ‘strong buy' penny stocks with over 300% possible upside

The stock price of Medicenna Therapeutics (MDNA) fell by 8.41% in the previous trading session. This is why.

Medicenna Therapeutics (MDNA) Stock: Why It Fell 8.41%

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q1 2023 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Arthur He - H.C. Wainwright Operator Greetings, and welcome to the Medicenna Therapeutics Corp. First Quarter Fiscal 2023 Earnings Call.

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q1 2023 Results - Earnings Call Transcript

-- Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed underwritten public offering of units (the “Units”) of the Company in Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately US$20 million, before deducting underwriting commissions and Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 13,333,334 Units. Each Unit is comprised of one common share and one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share at a price of US$1.85 per common share, subject to adjustment in certain events, during a period of 60 months following the date of the closing of the Offering.

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units (the “Unit”) of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”). The gross proceeds to the Company from the Offering are expected to be approximately US$20 million, before deducting underwriting discounts and commission and other expenses. Each Unit will be comprised of one common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share at a price of US$1.85 per common share, subject to adjustment in certain events, during a period of 60 months following the date of the closing of the Offering.

Medicenna Announces Pricing of US$20 Million Public Offering of Units

TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the “Units”) in the United States (the “Offering”). Each Unit will be comprised of one common share and one warrant to purchase common shares (a “Warrant” and, collectively, the “Warrants”).

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights.

Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022

-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study's low and mid-stage dose escalation cohorts

News for Medicenna Therapeutics Corp Stock (MDNA)